Sarepta's ESSENCE Study Shows Mixed Results for Duchenne Muscular Dystrophy Therapies Despite Missing Primary Endpoint
Key Insights
Sarepta Therapeutics completed its ESSENCE confirmatory study for AMONDYS 45 and VYONDYS 53, which failed to achieve statistical significance on the primary endpoint of 4-step ascend velocity at 96 weeks (P=0.309).
When excluding COVID-19 impacted participants, the study showed a clinically meaningful 30% reduction in disease progression (LSM 0.11 steps/second, P=0.09) over two years.
The company plans to meet with the FDA to discuss converting from accelerated to traditional approval based on encouraging trends and substantial real-world evidence showing multi-year benefits.
Sarepta Therapeutics has completed its pivotal ESSENCE confirmatory study for two Duchenne muscular dystrophy (search) (DMD (search)) therapies, revealing mixed results that highlight both the challenges of conducting ultra-rare disease trials and the potential clinical benefits of exon-skipping treatments.
The global Phase 3 randomized, double-blind, placebo-controlled study evaluated AMONDYS 45 (casimersen) and VYONDYS 53 (golodirsen) in 225 patients aged 6-13 years with DMD (search) amenable to exon 45 or 53 skipping. While the study failed to meet statistical significance on its primary endpoint of 4-step ascend velocity at 96 weeks, with an observed difference of 0.05 steps/second in least square means (P=0.309), the results revealed encouraging trends favoring treatment over placebo.
COVID-19 Impact Reveals Meaningful Treatment Effect
The nine-year study period encompassed the COVID-19 pandemic, which significantly impacted study participation and outcomes. When researchers excluded data from the 57 participants whose double-blind period overlapped with the pandemic, the results showed a more pronounced treatment effect. Among the remaining 168 non-COVID impacted participants, treated patients demonstrated a 30% reduction in disease progression (LSM 0.11 steps/second, P=0.09) over two years compared to placebo—a change the company describes as clinically meaningful.
"While the ESSENCE study did not meet statistical significance on its primary endpoint, we believe the results demonstrated a clear treatment effect, showing clinically meaningful functional outcomes for people with Duchenne who have mutations amenable to skipping exons 45 or 53," said Louise Rodino-Klapac, Ph.D., president of research & development and technical operations at Sarepta.
Safety Profile Remains Favorable
The ESSENCE study reinforced the established safety profile of Sarepta's phosphorodiamidate morpholino oligomer (PMO) therapies, with no new safety signals identified. Adverse events were predominantly mild (88%) or moderate (10.3%) and comparable between treatment and placebo groups. The most common treatment-emergent adverse events (≥10%) included vomiting, nasopharyngitis, pyrexia, headache, cough, fall, and upper respiratory infections.
Real-World Evidence Supports Clinical Benefits
For more than a decade, Sarepta's PMO therapies have treated over 1,800 amenable patients worldwide, from infants as young as 7 months to adults in their 30s. Real-world studies have demonstrated substantial clinical benefits, including a 7.5-year delay in the need for nighttime ventilation with VYONDYS 53 treatment and statistically significant slowing of lung function decline with AMONDYS 45.
Across the PMO portfolio, real-world evidence indicates multi-year mortality benefits, delays in loss of ambulation of 3-4 years, substantial reduction in risk of reaching a left ventricular ejection fraction below 55%, and significant reductions in emergency room and hospital visits.
Craig McDonald, M.D., professor and chair of the UC Davis Health (search) Department of Physical Medicine and Rehabilitation and an ESSENCE study investigator, noted: "In the trial and my clinical practice, I've followed boys and young men treated with casimersen and golodirsen since their initial approvals and, in my opinion, these therapies can help preserve critical functions like walking, stair climbing and feeding themselves."
Regulatory Path Forward
Based on the encouraging ESSENCE trends, substantial real-world evidence, and positive safety profile, Sarepta intends to schedule a meeting with the FDA to discuss converting from accelerated to traditional approval for both therapies. The completion of ESSENCE is expected to fulfill the primary postmarketing requirement for these treatments.
Strong Financial Performance Amid Strategic Restructuring
Sarepta reported solid Q3 2025 financial performance with net product revenues of $370.0 million, comprising $238.5 million from PMO therapies and $131.5 million from ELEVIDYS. Total revenues reached $399.4 million for the quarter, though this represented a decrease from $467.2 million in the same period of 2024, primarily due to reduced ELEVIDYS shipments following the suspension of non-ambulatory patient treatments in June 2025.
The company strengthened its financial position through several strategic initiatives, including refinancing a majority portion of its 2027 convertible notes to 2030, achieving cost savings above restructuring targets, and reporting positive cash flow for the quarter.
Pipeline Developments and Future Outlook
Beyond the PMO portfolio, Sarepta continues advancing multiple siRNA programs with readouts expected in early 2026 for facioscapulohumeral muscular dystrophy (search) (FSHD (search)) and myotonic dystrophy type 1 (search) (DM1 (search)) Phase 1/2 studies. The company remains on track to initiate a clinical trial for Huntington's disease (search) by the end of 2025.
CEO Doug Ingram emphasized the company's commitment to the Duchenne community: "We are pleased to have met our primary post-marketing obligation with the completion of ESSENCE, a particularly challenging trial to execute in the context of these ultra-rare diseases that heterogeneously degenerate over the course of decades."
The ESSENCE results underscore both the complexity of conducting confirmatory studies in ultra-rare diseases and the importance of real-world evidence in demonstrating therapeutic value. As Sarepta prepares for FDA discussions, the combination of clinical trial data and extensive real-world experience may provide a compelling case for traditional approval of these established DMD (search) therapies.